Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Portola Pharmaceuticals Inc    PTLA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
48.64(c) 47.73(c) 48.49(c) 49.15(c) 49.28(c) Last
811 000 641 943 636 957 556 738 336 172 Volume
-0.63% -1.87% +1.59% +1.36% +0.26% Change
More quotes
Financials ($)
Sales 2017 20,3 M
EBIT 2017 -287 M
Net income 2017 -287 M
Finance 2017 311 M
Yield 2017 -
Sales 2018 243 M
EBIT 2018 -199 M
Net income 2018 -179 M
Finance 2018 148 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 143x
EV / Sales2018 12,6x
Capitalization 3 216 M
More Financials
Company
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders, and inflammation.Its development-stage portfolio consists of the compounds including Betrixaban, a novel oral once-daily inhibitor of... 
More about the company
Surperformance© ratings of Portola Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on PORTOLA PHARMACEUTICALS IN
11/10 PORTOLA PHARMACEUTICALS : Announces New APEX Study Sub-Analyses Data on Betrixab..
11/09 PORTOLA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
11/09 PORTOLA PHARMACEUTICALS : Appoints Industry Veteran John H. Lawrence, M.D., as S..
11/07 PORTOLA PHARMACEUTICALS : Announces New APEX Study Sub-Analyses Data on Betrixab..
11/06 PORTOLA PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fin..
11/06 PORTOLA PHARMACEUTICALS : posts 3Q loss
11/06 PORTOLA PHARMACEUTICALS : Reports Third Quarter 2017 Financial Results and Provi..
11/06 Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pro..
11/06 Portola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as ..
11/06 PORTOLA PHARMACEUTICALS INC : Portola Pharmaceuticals, Inc. to Host Earnings Cal..
More news
Sector news : Biotechnology & Medical Research - NEC
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/16 PORTOLA PHARMACEUTICALS : The Ultra Long Views
11/15 YOUR DAILY PHARMA SCOOP : Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA A..
11/14 PORTOLA PHARMACEUTICALS : Valuable Assets Likely To Counterbalance Management Wo..
11/10 Puma Biotechnology Faces Balance Sheet Anxiety
11/09 YOUR DAILY PHARMA SCOOP : Portola Upside, Novartis Reports Positive Cosentyx Dat..
Chart PORTOLA PHARMACEUTICALS IN
Duration : Period :
Portola Pharmaceuticals In Technical Analysis Chart | PTLA | US7370101088 | 4-Traders
Technical analysis trends PORTOLA PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 74,3 $
Spread / Average Target 51%
EPS Revisions
Managers
NameTitle
William Lis Chief Executive Officer & Director
Hollings Chase Renton Chairman
Mardi C. Dier Chief Financial Officer & Executive Vice President
John T. Curnutte Executive Vice President-Research & Development
John H. Lawrence Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
PORTOLA PHARMACEUTICALS INC119.61%3 216
CELLTRION, INC.--.--%24 558
INCYTE CORPORATION5.19%22 258
IQVIA HOLDINGS INC37.36%22 074
LONZA GROUP59.52%19 560
ALNYLAM PHARMACEUTICALS, INC.240.57%12 538